Agoracom: Small Cap Investment - Resverlogix Corp.

...We Welcome You To The Resverlogix HUB withIn The AGORACOM COMMUNITY!

Reply New Message

Back To Forum List View

ERA-EDTA 2019 Symposium: Vascular calcification in kidney disease: Epigenetics as a novel approach?

BearDownAZ

Apr 14, 2019 09:23AM

Re: ERA-EDTA 2019 Symposium: Vascular calcification in kidney disease: Epigenetics as a novel approach?

tada

Apr 14, 2019 12:29PM

Re: ERA-EDTA 2019 Symposium: Vascular calcification in kidney disease: Epigenetics as a novel approach?

BearDownAZ

Apr 14, 2019 06:17PM

Re: ERA-EDTA 2019 Symposium: Vascular calcification in kidney disease: Epigenetics as a novel approach?

BearDownAZ

May 29, 2019 05:07PM

ERA-EDTA 2019 June 13-16

BearDownAZ

Jun 11, 2019 07:28PM

Re: ERA-EDTA 2019 June 13-16

BearDownAZ

Jun 12, 2019 07:57PM

Re: ERA-EDTA 2019 June 13-16

BearDownAZ

Jun 12, 2019 08:09PM

BearDownAZ

Rank: President [?]

Points: 25003 [?]

Votes: 68 Score: 4.5 [?]

Your Vote:

Please Log In to Vote

Did you know? You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)

Re: ERA-EDTA 2019 June 13-16

in response to

ERA-EDTA 2019 June 13-16

BearDownAZ

posted on Jun 14, 2019 09:14AM

The ERA-EDTA poster on FGF23 is now posted:

Apabetalone, a Selective Bromodomain and Extra-Terminal (BET) Inhibitor, Reduces Serum FGF23 in Cardiovascular Disease and Chronic Kidney Disease Patients.

2 Recommendations

Re: ERA-EDTA 2019 Symposium: Vascular calcification in kidney disease: Epigenetics as a novel approach?